A Comparative Study of Sequential Therapy and Standard Triple Therapy for Helicobacter pylori Infection: A Randomized Multicenter Trial

被引:74
作者
Zhou, Liya [1 ]
Zhang, Jianzhong [2 ]
Chen, Minhu [3 ]
Hou, Xiaohua [4 ]
Li, Zhaoshen [5 ]
Song, Zhiqiang [1 ]
He, Lihua [2 ]
Lin, Sanren [1 ]
机构
[1] Peking Univ, Hosp 3, Dept Gastroenterol, Beijing 100191, Peoples R China
[2] Chinese Ctr Dis Control & Prevent, Natl Inst Communicable Dis Control & Prevent, State Key Lab Infect Dis Prevent & Control, Collaborat Innovat Ctr Diag & Treatment Infect Di, Beijing, Peoples R China
[3] Sun Yat Sen Univ, Affiliated Hosp 1, Dept Gastroenterol, Guangzhou 510275, Guangdong, Peoples R China
[4] Huazhong Univ Sci & Technol, Union Hosp, Tongji Med Coll, Div Gastroenterol, Wuhan 430074, Peoples R China
[5] Second Mil Med Univ, Changhai Hosp, Dept Digest Dis, Shanghai, Peoples R China
关键词
CONCOMITANT THERAPY; OPEN-LABEL; ERADICATION; MANAGEMENT; LEVOFLOXACIN; METAANALYSIS; EFFICACY;
D O I
10.1038/ajg.2014.26
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
OBJECTIVES: Studies conducted in large populations of patients and providing full information on Helicobacter pylori (H. pylori) antibiotic resistance are needed to determine the efficacy of sequential therapy (SQT) against this pathogen. This study compared eradication rates with SQT and standard triple therapy (STT), and evaluated the impact of antibiotic resistance on outcomes. METHODS: The study population included adults with positive H. pylori culture presenting at four centers in China between March 2008 and December 2010. Patients were randomly assigned to 10 days of treatment with esomeprazole, amoxicillin, and clarithromycin (STT; n=140) or to 5 days of treatment with esomeprazole and amoxicillin, followed by 5 days of esomeprazole, clarithromycin, and tinidazole (SQT; n=140). Eradication was assessed 8 -12 weeks after treatment. RESULTS: There was no significant difference between the eradication rates achieved with STT (66.4 % (95 % confidence interval (CI) 59.3-74.3)) and SQT (72.1% (65.0-79.3); P=0.300) in either the intention-to-treat analysis or the per-protocol analysis (72.7 % (65.6-79.7) and 76.5 % (69.7-83.3), respectively; P = 0.475). Clarithromycin resistance (CLA-R, odds ratio (OR) = 8.34 (3.13-22.26), P < 0.001) and metronidazole resistance (MET-R, OR = 7.14 (1.52-33.53), P = 0.013) both independently predicted treatment failure in the SQT group. Patients in the SQT group with dual CLA-R and MET-R had a lower eradication rate (43.9 %) than those with isolated CLA-R (88.9 %, P=0.024) or isolated MET-R (87.8 %, P<0.001). CONCLUSIONS: H. pylori eradication rates with STT and SQT were compromised by antibiotic resistance. SQT may be suitable in regions with high prevalence of isolated CLA-R, but it is unsatisfactory when both CLA-R and MET-R are present.
引用
收藏
页码:535 / 541
页数:7
相关论文
共 50 条
  • [31] Sequential Therapy is Superior to Triple Therapy for Helicobacter pylori Infection in Children: A Meta-Analysis
    Huang, Yan
    Zhan, Xue
    [J]. INDIAN JOURNAL OF PEDIATRICS, 2016, 83 (04) : 307 - 315
  • [32] Sequential Therapy is Superior to Triple Therapy for Helicobacter pylori Infection in Children: A Meta-Analysis
    Yan Huang
    Xue Zhan
    [J]. The Indian Journal of Pediatrics, 2016, 83 : 307 - 315
  • [33] Sequential therapy versus standard triple-drug therapy for Helicobacter pylori eradication: Result of the HPFEZ randomised study
    Lahbabi, Mounia
    Alaoui, Samia
    El Rhazi, Karima
    El Abkari, Mohammed
    Nejjari, Chakib
    Amarti, Afaf
    Bennani, Bahia
    Mahmoud, Mustapha
    Ibrahimi, Adil
    Benajah, Dafr Allah
    [J]. CLINICS AND RESEARCH IN HEPATOLOGY AND GASTROENTEROLOGY, 2013, 37 (04) : 416 - 421
  • [34] Sequential Therapy Versus Tailored Triple Therapies for Helicobacter pylori Infection in Children
    Bontems, Patrick
    Kalach, Nicolas
    Oderda, Giuseppina
    Salame, Assad
    Muyshont, Laurence
    Miendje, D. Yvette
    Raymond, Josette
    Cadranel, Samy
    Scaillon, Michele
    [J]. JOURNAL OF PEDIATRIC GASTROENTEROLOGY AND NUTRITION, 2011, 53 (06) : 646 - 650
  • [35] Sequential Therapy Versus Standard Triple-Drug Therapy for Helicobacter pylori Eradication: a Systematic Review of Recent Evidence
    Kate, Vikram
    Kalayarasan, Raja
    Ananthakrishnan, Nilakantan
    [J]. DRUGS, 2013, 73 (08) : 815 - 824
  • [36] A randomised clinical trial of 10-day concomitant therapy and standard triple therapy for Helicobacter pylori eradication
    Heo, Jun
    Jeon, Seong Woo
    Jung, Jin Tae
    Kwon, Joong Goo
    Kim, Eun Young
    Lee, Dong Wook
    Seo, Hyang Eun
    Ha, Chang Yoon
    Kim, Hyun Jin
    Kim, Eun Soo
    Park, Kyung Sik
    Cho, Kwang Bum
    Lee, Si Hyung
    Jang, Byung Ik
    [J]. DIGESTIVE AND LIVER DISEASE, 2014, 46 (11) : 980 - 984
  • [37] Azithromycin based triple therapy versus standard clarithromycin based triple therapy in eradication of Helicobacter pylori infection in Iran: a randomized controlled clinical trial
    Sarkeshikian, Seyed Saeid
    Iranikhah, Abolfazl
    Ghadir, Mohammad Reza
    [J]. TURKISH JOURNAL OF GASTROENTEROLOGY, 2013, 24 (01) : 10 - 14
  • [38] Effectiveness of sequential v. standard triple therapy for treatment of Helicobacter pylori infection in children in Nairobi, Kenya
    Laving, A.
    Kamenwa, R.
    Sayed, S.
    Kimang'a, A. N.
    Revathi, G.
    [J]. SAMJ SOUTH AFRICAN MEDICAL JOURNAL, 2013, 103 (12): : 921 - 924
  • [39] Prospective Trial in Saudi Arabia Comparing the 14-day Standard Triple Therapy with the 10-day Sequential Therapy for Treatment of Helicobacter Pylori Infection
    Alsohaibani, Fahad
    Al Ashgar, Hamad
    Al Kahtani, Khalid
    Kagevi, Ingvar
    Peedikayil, Musthafa
    Alfadda, Abdulrahman
    Khan, Mohammed
    [J]. SAUDI JOURNAL OF GASTROENTEROLOGY, 2015, 21 (04) : 220 - 225
  • [40] Comparison of 10 and 14 days of triple therapy versus 10 days of sequential therapy for Helicobacter pylori eradication: A prospective randomized study
    Ennkaa, Abulgasim
    Shaath, Nabeel
    Salam, Abdul
    Mohammad, Ramzi M.
    [J]. TURKISH JOURNAL OF GASTROENTEROLOGY, 2018, 29 (05) : 549 - 554